Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population

Chana Wiesman, Esther Rose, Allison Grant, Adam Zimilover, Susan D. Klugman, Nicole Schreiber-Agus

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose:The notion of offering population-based screening to the Ashkenazi Jewish (AJ) population for the BRCA1/2 founder mutations continues to gain support. A program called the BRCAcommunity initiative was designed to identify the benefits and barriers associated with implementing this screening in a clinical setting.Methods:Interested AJ individuals were stratified into high-risk (HR) and low-risk (LR) groups based on self-reported cancer histories. Those at HR were offered traditional genetic counseling/testing; those at LR were offered group genetic counseling and subsidized AJ BRCA founder mutation testing.Results:During the pilot year, 62% of initial registrants and 53% of ultimate study participants were classified into the HR group. Among the 101 HR and 88 LR study participants, 8 and 2 BRCA carriers were identified, respectively. The LR carriers would have been missed by current mechanisms. Survey responses provided insight into the motivations and fears associated with pursuing testing, the efficacy of the initiative design, and challenges that exist on multiple levels, including the community, health-care providers, and insurance coverage.Conclusion:Although the medical value of identifying presymptomatic BRCA carriers in Ashkenazi Jews is evident, further measures need to be taken before this effort can be accomplished on a large scale.

Original languageEnglish (US)
Pages (from-to)529-536
Number of pages8
JournalGenetics in Medicine
Volume19
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Genetic Testing
Population
Genetic Counseling
Jews
Community Health Services
Mutation
Insurance Coverage
Health Insurance
Health Personnel
Fear
Motivation

Keywords

  • Ashkenazi Jewish
  • BRCA testing
  • group genetic counseling
  • hereditary cancer risk
  • population screening

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population. / Wiesman, Chana; Rose, Esther; Grant, Allison; Zimilover, Adam; Klugman, Susan D.; Schreiber-Agus, Nicole.

In: Genetics in Medicine, Vol. 19, No. 5, 01.05.2017, p. 529-536.

Research output: Contribution to journalArticle

Wiesman, Chana ; Rose, Esther ; Grant, Allison ; Zimilover, Adam ; Klugman, Susan D. ; Schreiber-Agus, Nicole. / Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population. In: Genetics in Medicine. 2017 ; Vol. 19, No. 5. pp. 529-536.
@article{500c9051fd304fa8a7e11539eeb96e32,
title = "Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population",
abstract = "Purpose:The notion of offering population-based screening to the Ashkenazi Jewish (AJ) population for the BRCA1/2 founder mutations continues to gain support. A program called the BRCAcommunity initiative was designed to identify the benefits and barriers associated with implementing this screening in a clinical setting.Methods:Interested AJ individuals were stratified into high-risk (HR) and low-risk (LR) groups based on self-reported cancer histories. Those at HR were offered traditional genetic counseling/testing; those at LR were offered group genetic counseling and subsidized AJ BRCA founder mutation testing.Results:During the pilot year, 62{\%} of initial registrants and 53{\%} of ultimate study participants were classified into the HR group. Among the 101 HR and 88 LR study participants, 8 and 2 BRCA carriers were identified, respectively. The LR carriers would have been missed by current mechanisms. Survey responses provided insight into the motivations and fears associated with pursuing testing, the efficacy of the initiative design, and challenges that exist on multiple levels, including the community, health-care providers, and insurance coverage.Conclusion:Although the medical value of identifying presymptomatic BRCA carriers in Ashkenazi Jews is evident, further measures need to be taken before this effort can be accomplished on a large scale.",
keywords = "Ashkenazi Jewish, BRCA testing, group genetic counseling, hereditary cancer risk, population screening",
author = "Chana Wiesman and Esther Rose and Allison Grant and Adam Zimilover and Klugman, {Susan D.} and Nicole Schreiber-Agus",
year = "2017",
month = "5",
day = "1",
doi = "10.1038/gim.2016.154",
language = "English (US)",
volume = "19",
pages = "529--536",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population

AU - Wiesman, Chana

AU - Rose, Esther

AU - Grant, Allison

AU - Zimilover, Adam

AU - Klugman, Susan D.

AU - Schreiber-Agus, Nicole

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Purpose:The notion of offering population-based screening to the Ashkenazi Jewish (AJ) population for the BRCA1/2 founder mutations continues to gain support. A program called the BRCAcommunity initiative was designed to identify the benefits and barriers associated with implementing this screening in a clinical setting.Methods:Interested AJ individuals were stratified into high-risk (HR) and low-risk (LR) groups based on self-reported cancer histories. Those at HR were offered traditional genetic counseling/testing; those at LR were offered group genetic counseling and subsidized AJ BRCA founder mutation testing.Results:During the pilot year, 62% of initial registrants and 53% of ultimate study participants were classified into the HR group. Among the 101 HR and 88 LR study participants, 8 and 2 BRCA carriers were identified, respectively. The LR carriers would have been missed by current mechanisms. Survey responses provided insight into the motivations and fears associated with pursuing testing, the efficacy of the initiative design, and challenges that exist on multiple levels, including the community, health-care providers, and insurance coverage.Conclusion:Although the medical value of identifying presymptomatic BRCA carriers in Ashkenazi Jews is evident, further measures need to be taken before this effort can be accomplished on a large scale.

AB - Purpose:The notion of offering population-based screening to the Ashkenazi Jewish (AJ) population for the BRCA1/2 founder mutations continues to gain support. A program called the BRCAcommunity initiative was designed to identify the benefits and barriers associated with implementing this screening in a clinical setting.Methods:Interested AJ individuals were stratified into high-risk (HR) and low-risk (LR) groups based on self-reported cancer histories. Those at HR were offered traditional genetic counseling/testing; those at LR were offered group genetic counseling and subsidized AJ BRCA founder mutation testing.Results:During the pilot year, 62% of initial registrants and 53% of ultimate study participants were classified into the HR group. Among the 101 HR and 88 LR study participants, 8 and 2 BRCA carriers were identified, respectively. The LR carriers would have been missed by current mechanisms. Survey responses provided insight into the motivations and fears associated with pursuing testing, the efficacy of the initiative design, and challenges that exist on multiple levels, including the community, health-care providers, and insurance coverage.Conclusion:Although the medical value of identifying presymptomatic BRCA carriers in Ashkenazi Jews is evident, further measures need to be taken before this effort can be accomplished on a large scale.

KW - Ashkenazi Jewish

KW - BRCA testing

KW - group genetic counseling

KW - hereditary cancer risk

KW - population screening

UR - http://www.scopus.com/inward/record.url?scp=85021700971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021700971&partnerID=8YFLogxK

U2 - 10.1038/gim.2016.154

DO - 10.1038/gim.2016.154

M3 - Article

VL - 19

SP - 529

EP - 536

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 5

ER -